ORIGINAL RESEARCH
ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer’s Disease Hussein N. Yassine, MD; Qingru Feng, MSc; Jiarong Chiang, BSc; Larissa M. Petrosspour, BSc; Alfred N. Fonteh, PhD; Helena C. Chui, MD; Michael G. Harrington, MB, ChB, FRCP
Background-—Animal and human studies indicate that ABCA1-mediated cholesterol transport is important in Alzheimer’s disease (AD). We hypothesized that the efficiency of cerebrospinal fluid (CSF) to facilitate ABCA1-mediated cholesterol efflux would be reduced in participants with mild cognitive impairment (MCI) or AD compared with cognitively healthy participants. Methods and Results-—CSF was collected from a cross-sectional study of cognitively healthy participants (n=47) and participants with MCI (n=35) or probable AD (n=26).The capacity of CSF to mediate cholesterol transport was assessed using a BHK cell line that can be induced to express the ABCA1 transporter. ABCA1-mediated cholesterol efflux capacity was 30% less in participants with MCI or AD compared with cognitively healthy participants (P
ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer’s Disease Hussein N. Yassine, MD; Qingru Feng, MSc; Jiarong Chiang, BSc; Larissa M. Petrosspour, BSc; Alfred N. Fonteh, PhD; Helena C. Chui, MD; Michael G. Harrington, MB, ChB, FRCP
Background-—Animal and human studies indicate that ABCA1-mediated cholesterol transport is important in Alzheimer’s disease (AD). We hypothesized that the efficiency of cerebrospinal fluid (CSF) to facilitate ABCA1-mediated cholesterol efflux would be reduced in participants with mild cognitive impairment (MCI) or AD compared with cognitively healthy participants. Methods and Results-—CSF was collected from a cross-sectional study of cognitively healthy participants (n=47) and participants with MCI (n=35) or probable AD (n=26).The capacity of CSF to mediate cholesterol transport was assessed using a BHK cell line that can be induced to express the ABCA1 transporter. ABCA1-mediated cholesterol efflux capacity was 30% less in participants with MCI or AD compared with cognitively healthy participants (P
